Confidential - For the use of registered medical practitioner only






BRINGING Hope to Lite

in Relapsed/Refractory cHL patients

ADCETRIS is an effective treatment for r/r HL in clinical practice¹



chemotherapy 2,4,5,6**



chemotherapy ^{2,3*}

High, durable rates of remission and survival in the real world⁷

1000-

*Based on retrospective multi-center studies from the UK/Germany and from the USA.^{2,3} **Based on retrospective studies from Greece, Norway, UK/Germany and the USA. ^{2,4,5,6} r/r HL: relapsed or refractory Hodgkin lymphoma; OS: overall survival; PFS: progression free-survival

References:

- Angelopoulou MK, Vassilakopoulos TP, Batsis I, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: the Hellenic experience. Hematol Oncol. 2018;36:174-181.
- 2. Zagadailov EA, Corman S, Chirikov V, et al. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk Lymphoma. 2018;59:1413-1419.
- 3. Badar T, Epperla N, Szabo A et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4:47-54.
- 4. Tsirigotis P, Vassilakopoulos T, Batsis I, et al. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: a nationwide analysis. Hematol Oncol. 2018;36:645-650.
- 5. Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol.2017;92:879-884.
- 6. Fossa A, Smeland K, Fagerli UM, et al. Brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: real life experience in Norway 2011-2016. Acta Oncol. 2020;59:101-105.
- 7. Plattel WJ, Bergamasco A, Trinchese F, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2021 July 29 [epub ahead of print].

Disclaimer: This information is solely intended for the use of Registered Medical Practitioner only. This information should not be used or shared or distributed to any other person / party and should be strictly by the intended parties for the intended purposes only. Registered Healthcare Practitioner / Registered Medical Practitioner shall apply their independent medical judgement for assessing any patient. Takeda makes no representation or warranty concerning the information / content provided, and assumes no responsibility for the accuracy of the information or content or for any opinion furnished or any outcome based on the application of such information. This material contains copyright protected information, content; the use of which is limited by law and this material cannot be reproduced, replicated, used or modified by any person for their own use or further distribution.

For more information, please refer to full Prescribing Information.

TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. **VADCET** is a registered trademark of Millennium Pharmaceuticals, Inc. C-APROM/IN/ADCE/0029

Scan QR code for API

